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Background: Salivary gland-type tumors originating in the nasopharynx are rare, and only a
few  articles about mucoepidermoid carcinomas (MEC) in this location have been reported.
We  describe one case of nasopharyngeal MEC and, based on a review of the literature, dis-
cuss different therapeutic approaches that can be taken regarding the result of histological
ﬁndings, radiological tests and extent of disease.
Case presentation: A 47-year-old woman diagnosed with mucoepidermoid carcinoma of
nasopharynx, T1 N3 M0 (stage IV-B) was treated in 2007 with a combination of radiothe-
rapy  and chemotherapy to a maximum dose of 70 Gy and concomitant Cisplatin during the
radiation. One year later, with the head and neck disease under control, mediastinal nodes
relapse appeared which were treated with exclusive radiotherapy to a maximum dose of
65  Gy. One year after the ﬁrst relapse, a second relapse was detected in the right lung, next
to  the previously treated mediastinal regions, and the patient initiated a treatment with
exclusive chemotherapy based on TPF scheme.
Conclusion: For limited or resectable MEC, combined surgery with radiotherapy, orradiochemotherapy, should be considered the main treatment policy. On the other hand,
in  poorly differentiated, unresectable tumors or nasopharyngeal MEC, radiochemotherapy
could be currently the main treatment approach.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
Salivary gland-type tumors of nasopharynx have been
1–3.  Backgrounducoepidermoid carcinoma (MEC) is a common malignancy
n the salivary glands, especially, in the major salivary glands
nd intra-oral minor salivary glands.1 MEC  has been less
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frequently reported to arise from other sites, including the
lung, nasal cavity, paranasal sinuses and nasopharynx.c@salud.madrid.org (A.H. Morón), angel.monteroluis@gmail.com
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scarcely reported in the literature. The etiopathogenesis,
treatment and prognosis of salivary gland-type malig-
nant tumors are still uncertain. We  describe one case of
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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nasopharyngeal MEC  and, based on a review of the literature,
discuss different therapeutic approaches that can be taken
regarding the result of histological ﬁndings, radiological tests
and extent of disease.
2. Case  presentation
A 47-year-old woman with a 40-pack per year history of smok-
ing tobacco and occasional alcohol consumption presented
with bilateral lymph neck nodes, odynophagia and left neck
pain. Her past medical history was only signiﬁcant for a pre-
vious episode of infectious mononucleosis twenty-ﬁve years
ago. She had no other medical history of note.
Physical examination revealed the presence of palpable
bulky adenopathies in the left neck encompassing levels II–V,
and levels II–III on the right neck. A CT-scan conﬁrmed the
presence of bilateral cervical lymph nodes along with asym-
metry in the left cavum. Magnetic-resonance imaging revealed
an anomalous enhancement in the left cavum suggesting
a neuplastic growth. The PET-CT evidenced an increasing
uptake of 18F-FDG in the left nasopharynx and cervical lymph
nodes (see Fig. 1).
The biopsy of the nasopharynx and cervical lymph nodes
evidenced the presence of multiple nests of cells forming
ducts with eosinophilic material inside and the expression of
low molecular weight cytokeratins detected by immunohis-
tochemistry. All ﬁndings were consistent with a high grade
MEC.
A ﬁnal diagnosis of mucoepidermoid carcinoma of the
cavum was established, cT1cN3M0 stage IVB according to the
AJCC 7th edition.4
The case was evaluated in the head and neck tumors
multidisciplinary recommending treatment with concomitant
radiochemotherapy. The patient underwent radiotherapy with
conventional 2 Gy/day fractionation up to a total dose of 50 Gy
to the bilateral uninvolved II–V neck levels and retropharyn-
geal area. Palpable adenopathies less than 3 cm in diameter
Fig. 1 – Diagnostic PET-CT with an increasing of tracer
uptake of 18F-FDG in left nasopharynx and cervical lymph
nodes.iotherapy 1 8 ( 2 0 1 3 ) 117–120
were boosted up to 60 Gy. Finally, the gross tumor located on
nasopharynx and lymph nodes greater than 3 cm in diame-
ter received a total dose of 70 Gy with identical fractionation.
Together with the radiation therapy, the patient received 3
courses of cisplatin (CDDP) at a dose of 100 mg/m2 each 21
days, and 3 additional courses of chemotherapy after com-
pletion of simultaneous radiochemotherapy based upon the
Al-Sarraf regimen with CDDP (100 mg/m2, day 1) and 5-FU
(1 g/m2, days 1–5) each 21 days.5
A 18F-FDG-PET/CT performed 3 months after treatment did
not reveal any increase of metabolism, nor of nasopharynx or
lymphatic cervical levels. Only a slight focal increased tracer
uptake was detected in mediastinal and right lung hilus nodes
without being able to distinguish between tumor tissue and
infectious process.
Four month later, a repeated 18F-FDG-PET/CT conﬁrmed an
increase of tracer uptake in the previous hilum and precaval
lymphadenopathies without other signiﬁcant data in the rest
of the examination (see Fig. 2). With the suspicion of tumor
relapse, a CT guided FNA biopsy of the nodes was consid-
ered but the patient declined this approach. The case was
discussed in the head and neck tumors multidisciplinary com-
mittee recommending that the images were assumed as viable
tumor and a salvage treatment was proposed. The patient
underwent radiotherapy to the mediastinal and hilum areas
up to a total dose of 50.4 Gy (1.8 Gy/fraction/day). Signiﬁcant
lymphadenopathies by 18F-FDG-PET/CT were boosted a ﬁnal
dose of 65 Gy (1.8 Gy/fraction/day). Concomitant chemother-
apy with CDDP was rejected because of the progression of
disease with this scheme. Targeted treatment based on Cetux-
imab  or Bevazucimab was dismissed due to the negative
immunohistochemical analysis and PCR sequencing of EGFR
and VEGR in the previous sample.showed a good response in the hilum and mediasti-
nal nodes treated, however, pathological images of new
Fig. 2 – 18F-FDG-PET/CT, after 4 months of treatment, with
an increased of tracer uptake in the right lung hilum and
precaval lymphadenopathies without another signiﬁcant
data in the rest of the examination.
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Fig. 3 – 18F-FDG-PET/CT, after treatment of lung and hilum
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pelapse, with a good response in the treated ﬁelds.
ymphadenopathies in other mediastinal localizations were
etected together with a suspicious image  in lung parenchyma
see Fig. 3). A ﬁbrobroncoscopy evidenced an occlusive bron-
uial mass, with biopsy of highly undifferentiated carcinoma
ells unable to rule out that it was a metastasis of the initial
ucoepidermoid carcinoma of the nasopharynx due to the
igh indifferenciation of the cells in the sample. A FNA biopsy
f the transcarinal lymphadenopaties also showed carcinoma
ells in the histological analysis. The patient was considered
noperable undergoing systemic chemotherapy with a pacli-
axel, cisplatin and 5-FU without response. The patient died
ecause of metastatic tumor progression 4 years after initial
iagnosis.
. Discussion
ucoepidermoid carcinoma was ﬁrst described by Stewart
t al. in 19456 as a rare malignancy that arises in the major
nd minor salivary glands of the head and neck. MEC repre-
ents approximately one third of all carcinomas developing
n these regions,7 being the most common carcinoma in the
arotid gland.8
Nasopharyngeal MEC  comprising less than 15% of all
asopharyngeal salivary gland malignancies, that is, approxi-
ately 3% of all nasopharyngeal carcinomas.9 Because of this,
here are few articles that report only nasopharyngeal MEC
nd a few more  that join nasopharyngeal MEC with other head
nd neck MECs or with other nasopharyngeal salivary gland
ype malignancies.
MEC  has a female predominance, with the highest preva-
ence in the ﬁfth decade of life. As in other tumors, the usual
ymptoms are related to the location of the primary tumor,
ts inﬁltration of the surrounding structures, and the pres-
nce of cervical lymph nodes and distant metastases. Nasal
leeding and obstruction, headache, facial numbness, tinnitus
r hearing loss, deafness and diplopia are the most common
resentations.10 The incidence of nasopharyngeal salivarytherapy 1 8 ( 2 0 1 3 ) 117–120 119
gland type malignancy metastasis in the context of MEC  is
low, less than 20–25% according to some authors.11
On the pathology exam, MEC is constituted by acinic cell
cancer derived from cells of the terminal ducts and interca-
lated ducts.7 Histochemical studies have detected that the
tumor glands are like nests with positive mucous cells for
mucin staining. Immunohistochemically, the lesions are pos-
itive for cytokeratins (CKs), p63, and MUC1, but negative
for alpha-smooth muscle actin and EBER mRNA.12 Addition-
ally, the t(11;19)(q21;p13) translocation resulting in MAML2
gene rearrangement has been identiﬁed in a majority of MEC
regardless of the grade and has been suggested as an addi-
tional marker of favorable prognosis, being a potentially useful
conﬁrmatory diagnostic test if positive.13
The different behavior of MEC compared with nasopha-
ryngeal squamous cell carcinomas reﬂects the controversies
in the mainstay of treatment. The best approach for local
MEC  is not clear. Surgery and radiotherapy (or concomitant
radiochemotherapy) remain as the more  contrasted options.12
It is unclear if MEC is a radiosensitive or a radioresistant
tumor. Different authors have reported their experience with
radiotherapy alone obtaining good control rates of the local
disease in early stage tumors. However, many  of these case
series include MEC from different locations so it might be too
early to reach the conclusion that nasopharyngeal MEC  can be
radiosensitive.11 Based on the reported cases, it appears that
poorly differentiated tumors are those that respond better to
radiation.
The role of adjunctive radiotherapy after surgery is an
approach in this kind of tumors although limited to the
location. Post-operative radiotherapy acts as and important
complement to the surgery improving the local control rates in
patients with positive surgical margins. Because of this, com-
bined surgery with radiotherapy is the main treatment policy
for resectable MEC.14,15
Technological advances in radiotherapy allow limiting the
highest dose to the tumor without affecting surrounding
healthy organs. High-dose radiotherapy has been related to
better outcomes in many  localized tumors, like epidermoid
cervix cancer or other squamous head and neck cancers.
Together with this, the use of radiosensitizing drugs in combi-
nation with radiotherapy, has further increased local control
of different tumors. Therefore, radical radiochemotherapy is
frequently used in advanced loco-regional disease in head
and neck tumors and nasopharyngeal tumors, the latter one
being a good example of these improvements. Chemotherapy
alone is mainly used for metastatic and advanced recurrent
disease in head and neck cancer without result so evident
in MEC. Cisplatin-based combination chemotherapy (such as
cisplatin and 5-ﬂuorouracil) has become a standard treat-
ment approach for metastatic. Finally, our patient received
chemotherapy alone when all the other therapies were
depleted.11
In the present case, we decided to treat the patient with
concomitant radiochemotherapy, considering that the tumor
was located in the nasopharynx, where radiochemotherapy
is considered the gold-standard treatment by all interna-
tional cancer guidelines.16 Moreover, due to the unclear
radiosensitivity of the MEC, we tried to increase the radiosen-
sitizing effect with a CDDP based scheme to increase the
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radiobiological effect of the radiation therapy. Furthermore,
due to the fact that Al-Sarraf scheme was at that time the
most contrasted radiochemotherapy treatment in nasopha-
ryngeal carcinomas, we used the whole scheme and added
adjuvant chemotherapy to complete the treatment. Finally,
this approach resulted in a very good response in the
treated areas without radiologic and metabolic relapse post-
radiochemotherapy. Also, it is important to note that the two
tumor recurrences presented by the patient were in the areas
where no radiotherapy, with or without chemotherapy, had
been administered previously.
4. Conclusions
For limited or resectable MEC, combined surgery with radio-
therapy (or radiochemotherapy) should be considered the
treatment of election. On the other hand, in poorly dif-
ferentiated, unresectable tumors or nasopharyngeal MEC,
radiochemotherapy could be currently the main treatment
approach.
Because of the low incidence of nasopharyngeal MEC, the
number of cases is relatively small for analysis. Prospective
multicenter studies are necessary to further evaluate the opti-
mal  treatment approaches and the most relevant prognostic
factors for these types of carcinomas.
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